Geulah Livshits
Stock Analyst at Chardan Capital
(4.34)
# 416
Out of 5,113 analysts
247
Total ratings
48.39%
Success rate
19.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Buy | $17 | $7.44 | +128.49% | 14 | Jan 13, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $12 | $4.48 | +167.86% | 17 | Jan 6, 2026 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $26 | $8.60 | +202.33% | 14 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 → $174 | $78.71 | +121.06% | 6 | Dec 16, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 → $8 | $0.66 | +1,112.12% | 14 | Dec 12, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 → $13 | $1.03 | +1,162.14% | 11 | Dec 9, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $74 | $53.69 | +37.83% | 16 | Nov 26, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $9.70 | +157.73% | 3 | Nov 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $5.00 | +300.00% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $11.34 | +85.19% | 6 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $4.03 | +123.33% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $26 | $13.82 | +88.13% | 17 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $2.75 | +518.18% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $6.55 | +129.01% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $272.91 | -19.39% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.58 | +207.26% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.60 | +587.50% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $2.36 | +154.24% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.06 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $7.76 | +428.35% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.85 | +321.05% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $45.30 | +359.16% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.91 | +1,661.14% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $11.01 | +717.44% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.97 | +0.76% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $24.75 | -27.27% | 1 | Oct 27, 2020 |
Lexeo Therapeutics
Jan 13, 2026
Maintains: Buy
Price Target: $17
Current: $7.44
Upside: +128.49%
Taysha Gene Therapies
Jan 6, 2026
Maintains: Buy
Price Target: $12
Current: $4.48
Upside: +167.86%
4D Molecular Therapeutics
Dec 18, 2025
Maintains: Buy
Price Target: $26
Current: $8.60
Upside: +202.33%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $110 → $174
Current: $78.71
Upside: +121.06%
Tenaya Therapeutics
Dec 12, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $0.66
Upside: +1,112.12%
Senti Biosciences
Dec 9, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $1.03
Upside: +1,162.14%
CRISPR Therapeutics AG
Nov 26, 2025
Maintains: Buy
Price Target: $82 → $74
Current: $53.69
Upside: +37.83%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $9.70
Upside: +157.73%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $5.00
Upside: +300.00%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $11.34
Upside: +85.19%
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $4.03
Upside: +123.33%
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $13.82
Upside: +88.13%
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.75
Upside: +518.18%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $6.55
Upside: +129.01%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $272.91
Upside: -19.39%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.58
Upside: +207.26%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.60
Upside: +587.50%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.36
Upside: +154.24%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.06
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $7.76
Upside: +428.35%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.85
Upside: +321.05%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $45.30
Upside: +359.16%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.91
Upside: +1,661.14%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $11.01
Upside: +717.44%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.97
Upside: +0.76%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $24.75
Upside: -27.27%